Cellis is a European biotech company, with a focus in cell-based oncology therapy. We have developed a breakthrough platform technology called Macrophage Drug Conjugate (MDC) for the treatment of solid tumors. MDC is based on the ground-breaking discovery of the biologic TRAIN mechanism, which enables efficient and highly targeted delivery of a wide range of active moieties and compounds directly into the cytoplasm of cancer cells. As a result, cancer cells are killed and tumor masses shrink. MDC also changes the tumor microenvironment creating immune resistance to cancer growth. Preparation is underway to progress our technology to the first in human clinical trials in Q3 2024.
